

IN THE CLAIMS:

Please cancel claims 2-10, and 21-25 without prejudice.

Please add the following new claims 26-39.

1 NR 26. (New) The method of claim 17, wherein said immunogen is an attenuated form of
2 human immunodeficiency virus.

1 NR 27. (New) The method of claim 26, wherein said immunogen has been attenuated by
2 removing all or part of the nef gene from the nucleic acid of said human immunodeficiency
3 virus.

1 NR 28. (New) The method of claim 26, wherein said immunogen is a subunit of said
2 human immunodeficiency virus.

1 NR 29. (New) The method of claim 28, wherein said immunogen is a gp120 subunit of
2 said human immunodeficiency virus.

1 NR 30. (New) The method of claim 28, wherein said immunogen is a gp160 subunit of
2 said human immunodeficiency virus.

1 NR 31. (New) The method of claim 17, wherein said immunogen is an inactivated human
2 immunodeficiency virus.

1 NR 32. (New) The method of claim 31, wherein said immunogen has been inactivated by
2 removing a sufficient portion of its genetic material so as to render it incapable of replicating.

1 NR 33. (New) The method of claim 32, wherein the genetic material removed from said
2 human immunodeficiency virus is a portion of a gene coding for a gag nucleocapsid protein.

1 NR 34. (New) The method of claim 31, wherein said human immunodeficiency virus has
2 been inactivated by exposure to a solution of betapropiolactone.

1 NR 35. (New) The method of claim 32 wherein, said immunogen is an infectious form of
2 human immunodeficiency virus administered in a subinfectious amount.

1 O_u. 36. (New) The method of claim 17 wherein, a cell mediated response is determined to
2 be present using a T-Cell proliferation assay if the uptake of thymidine by antigen-stimulated
3 cells is at least four-fold above background.

1 O_u 37. (New) The method of claim 17 wherein, a cell mediated response is determined to
2 be present using an IL-2 assay if the production of IL-2 by antigen-stimulated cells is at least
3 four-fold above background.

1 N_o 38. (New) A method of inducing a cell-mediated immune response against a human
2 immunodeficiency virus, without inducing a humoral response against said virus in a mammal
3 seronegative for said virus, comprising the steps of:

4 selecting an immunogen of said virus, wherein said immunogen is immunogenic in said
5 mammal; and

6 administering said immunogen in an amount sufficient to induce a cell mediated immune
7 response against said immunogen, wherein said amount is insufficient to induce a humoral
8 immune response against said immunogen.

1 N_o 39. (New) A method of inducing a cell-mediated immune response against an HIV
2 immunogen, without inducing a humoral response against said immunogen, in a human
3 immunodeficiency virus (HIV) seronegative mammal, comprising the steps of:

4 selecting an HIV immunogen, wherein said immunogen is immunogenic in said mammal;
5 and

6 administering said immunogen in an amount sufficient to induce a cell mediated immune
7 response against said immunogen, wherein said amount is insufficient to induce a humoral
8 immune response against said immunogen.--